false
0001716166
0001716166
2026-04-15
2026-04-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 15, 2026
Vivos
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39796 |
|
81-3224056 |
| (State
or other jurisdiction |
|
(Commission
|
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
7921
Southpark Plaza, Suite 210
Littleton,
Colorado 80120
(Address
of principal executive offices) (Zip Code)
(866)
908-4867
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
VVOS |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
April 15, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the
fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
The
information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release of the Company, dated April 15, 2026, announcing its financial results for the fiscal year ended December 31, 2025. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
VIVOS
THERAPEUTICS, INC. |
| |
|
| Dated:
April 15, 2026 |
By: |
/s/
Bradford Amman |
| |
Name: |
Bradford
Amman |
| |
Title: |
Chief
Financial Officer |
Exhibit
99.1
Vivos
Therapeutics Reports Full Year 2025 Financial Results
Full
Year 2025 revenue increased 16%
Integration
of The Sleep Center of Nevada and shift business model support path to improved revenues, margins and cash flow
Management
to Host Conference Call today at 5:00 pm ET
LITTLETON,
Colo., April 15, 2026
–
Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device
and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions,
including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the full year ended
December 31, 2025.
Full
Year 2025 Financial and Operating Summary
| |
● |
Revenue
was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year
over year increase of 16%. The increase in revenue was mainly due to an increase in sleep testing services and an increase in revenue
from the treatment of OSA patients at two Nevada locations of The Sleep Center of Nevada (SCN), both offset by the expected
wind down of Vivos Integrated Practice (VIP) enrollment revenue. Vivos acquired the operating assets of SCN in June 2025; |
| |
|
|
| |
● |
Gross
profit was $10.5 million for the year ended December 31, 2025 compared with $9.0 million for the full year ended December 31, 2024,
an increase of 17%; |
| |
|
|
| |
● |
Gross
margin remained at 60% for the years ended December 31, 2025 and December 31, 2024; |
| |
|
|
| |
● |
Operating
expenses for the year ended December 31, 2025 was $30.4 million, compared to $20.2 million for the year ended December 31, 2024,
the increase relating in part to costs associated with integrating and managing SCN operations and related OSA treatment centers;
|
| |
|
|
| |
● |
Vivos’
acquisition of the operating assets of SCN and investments in that business resulted in an operating loss of $19.9 million for the
full year ended December 31, 2025, versus a loss of $11.2 million for the year ended December 31, 2024; |
| |
|
|
| |
● |
Cash
and cash equivalents were $2.0 million as of December 31, 2025, and Vivos’ cash position was augmented subsequent to year end
by two financing transactions for aggregate gross proceeds of $6.8 million. |
Vivos’
2025 results of operations reflect its continued pivot in business strategy and steady decrease in its prior focus on enrolling and training
VIP dentists to sell Vivos’ proprietary OSA treatments. Vivos’ new business strategy is focused on contractual alliances
with and outright acquisitions of sleep specialty medical providers, sleep testing centers and other similar entities.
Kirk
Huntsman, Vivos’ Chairman and Chief Executive Officer, stated “2025 was a pivotal year for Vivos. We grew full-year revenue
by 16%, maintained gross margin despite significant investment, driven primarily by the continued ramp of our sleep testing services
and the integration of The Sleep Center of Nevada. While our operating loss reflects the upfront investments in this new model, we believe
these actions, together with recent significant cost-savings initiatives and strengthened capital structure, position Vivos to drive
higher top-line growth, better contribution margins, and a clear path toward our goal of cash flow positive operations by end of this
year.”
Vivos
encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time (details below), where
management will discuss further details on topics including Vivos’ strategic initiatives and the anticipated effect on Vivos’
near-term revenue growth and cash burn.
In
addition, further information on Vivos’ financial results is included on the attached condensed consolidated balance sheets and
statements of operations, and additional explanations of Vivos’ financial performance are provided in the Vivos’ Annual Report
on Form 10-K for the twelve months ended December 31, 2025, which was filed today with the Securities and Exchange Commission (“SEC”).
The full 10-K report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.
Conference
Call
To
access Vivos’ investor conference call, please dial (800) 717-1738 or (646) 307-1865 for international callers. A replay will be
available shortly after the call and can be accessed by dialing (844) 512-2921 or (412) 317-6671 for international callers. The passcode
for the replay is 1153783. The replay will be available until April 29, 2025
A
live webcast of the conference call is available on Vivos’ website at https://vivos.com/investor-relations. An online archive
of the webcast will be available on the Company’s website for 30 days following the call.
About
Vivos Therapeutics, Inc.
Vivos
Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing
innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities
such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration
(FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’
groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating
severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA
affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is
not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides
in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments
like CPAP are often mechanistic and fail to address the root causes of OSA.
Founded
in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions
of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs
of OSA patients more thoroughly.
Vivos
calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective
solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For
more information, visit www.vivos.com.
Cautionary
Note Regarding Forward-Looking Statements
This
press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”,
“expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”,
“hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to
identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions
and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control.
Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future
revenues and results of operations and the anticipated benefits of the Company’s new marketing and distribution model described
herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause
actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales
and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results
from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector;
(iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq
listing due to, among other things, a deficiency in its stockholders’ equity; (v) market and other conditions, and (vi) other risk
factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website
at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect
thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos
Investor Relations and Media Contact:
Bradford
Amman
Chief
Financial Officer and Investor Relations Contact
investors@vivoslife.com
-Tables
Follow-
VIVOS
THERAPEUTICS, INC.
Consolidated
Balance Sheets
December
31, 2025 and 2024
(In
Thousands, Except Per Share Amounts)
| | |
2025 | | |
2024 | |
| Current assets | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 2,029 | | |
$ | 6,260 | |
| Accounts receivable, net of allowance of $882 and $390, respectively | |
| 1,581 | | |
| 430 | |
| Prepaid expenses and other current assets | |
| 774 | | |
| 783 | |
| Total current assets | |
| 4,384 | | |
| 7,473 | |
| | |
| | | |
| | |
| Long-term assets | |
| | | |
| | |
| Goodwill | |
| 8,572 | | |
| 2,843 | |
| Property and equipment, net | |
| 3,757 | | |
| 3,311 | |
| Operating lease right-of-use asset | |
| 4,166 | | |
| 1,032 | |
| Intangible assets, net | |
| 4,045 | | |
| 409 | |
| Deposits and other | |
| 228 | | |
| 216 | |
| Total assets | |
$ | 25,152 | | |
$ | 15,284 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable | |
$ | 1,679 | | |
$ | 1,098 | |
| Accrued expenses | |
| 5,988 | | |
| 2,234 | |
| Current portion of contract liabilities | |
| 479 | | |
| 896 | |
| Current portion of operating lease liability | |
| 672 | | |
| 477 | |
| Current portion of financing lease liability | |
| 55 | | |
| - | |
| Current portion of debt | |
| 8,353 | | |
| - | |
| Other current liabilities | |
| 850 | | |
| 273 | |
| Total current liabilities | |
| 18,076 | | |
| 4,978 | |
| | |
| | | |
| | |
| Long-term liabilities | |
| | | |
| | |
| Contract liabilities, net of current portion | |
| - | | |
| 97 | |
| Employee retention credit liability | |
| 2,904 | | |
| 1,220 | |
| Operating lease liability, net of current portion | |
| 3,840 | | |
| 1,035 | |
| Financing lease liability, net of current portion | |
| 113 | | |
| - | |
| Debt, net of current portion | |
| 469 | | |
| - | |
| Other liabilities | |
| 1,300 | | |
| - | |
| Total liabilities | |
| 26,702 | | |
| 7,330 | |
| | |
| | | |
| | |
| Commitments and contingencies | |
| - | | |
| - | |
| | |
| | | |
| | |
| Stockholders’ equity/(deficit) | |
| | | |
| | |
| Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding | |
| - | | |
| - | |
| Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 9,286,609 shares as of December 31, 2025 and 5,889,520 shares as December 31, 2024 | |
| 1 | | |
| - | |
| Additional paid-in capital | |
| 123,866 | | |
| 112,141 | |
| Accumulated deficit | |
| (125,357 | ) | |
| (104,187 | ) |
| Total stockholders’ equity/(deficit) | |
| (1,490 | ) | |
| 7,954 | |
| Non-controlling interest | |
| 60 | | |
| - | |
| Total equity/(deficit) | |
| (1,550 | ) | |
| 7,954 | |
| | |
| | | |
| | |
| Total liabilities and equity/(deficit) | |
$ | 25,152 | | |
$ | 15,284 | |
VIVOS
THERAPEUTICS, INC.
Consolidated
Statements of Operations
Years
Ended December 31, 2025 and 2024
(In
Thousands, Except Per Share Amounts)
| | |
2025 | | |
2024 | |
| Revenue | |
| | | |
| | |
| Product revenue | |
$ | 6,487 | | |
$ | 7,874 | |
| Service revenue | |
| 10,956 | | |
| 7,157 | |
| Total revenue | |
| 17,443 | | |
| 15,031 | |
| | |
| | | |
| | |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | |
| 6,901 | | |
| 6,012 | |
| | |
| | | |
| | |
| Gross profit | |
| 10,542 | | |
| 9,019 | |
| | |
| | | |
| | |
| Operating expenses | |
| | | |
| | |
| General and administrative | |
| 27,727 | | |
| 17,878 | |
| Sales and marketing | |
| 1,400 | | |
| 1,731 | |
| Depreciation and amortization | |
| 1,309 | | |
| 581 | |
| | |
| | | |
| | |
| Total operating expenses | |
| 30,436 | | |
| 20,190 | |
| | |
| | | |
| | |
| Operating loss | |
| (19,894 | ) | |
| (11,171 | ) |
| | |
| | | |
| | |
| Non-operating income (expense) | |
| | | |
| | |
| Other expense | |
| (1,481 | ) | |
| (110 | ) |
| Other income | |
| 145 | | |
| 145 | |
| Loss before income taxes | |
| (21,230 | ) | |
| (11,136 | ) |
| | |
| | | |
| | |
| Net loss | |
$ | (21,230 | ) | |
$ | (11,136 | ) |
| Net loss attributable to non-controlling interest | |
| (60 | ) | |
| - | |
| Net loss attributable to stockholders | |
$ | (21,170 | ) | |
$ | (11,136 | ) |
| | |
| | | |
| | |
| Net loss per share (basic and diluted) | |
$ | (2.07 | ) | |
$ | (2.22 | ) |
| Weighted average number of shares of Common Stock outstanding (basic and diluted) | |
| 10,273,881 | | |
| 5,019,886 | |
